Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
-$0.41 today
- Market cap
- $192.17M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
Volume 0.17M
Average 0.26M
RNAC Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Cartesian Therapeutics, Inc.NASDAQ: RNAC
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $27K (cash outflow) fell 97.5% year over year, behind the -53.9% change in trailing-twelve-month capital expenditures. Sequentially, it fell 94.5% from the prior quarter. Over 3 fiscal years it compounded at +65.6% a year.
Context
- Capital expenditures amounted to 195.0% of revenue in FY2025, up 171.6 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -97.5% toward the trailing-twelve-month pace of -53.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (5.45M) USD
- Year-over-year change
- +40.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.45M) | +40.0% |
| FY2024 | 2024-12-31 | (9.09M) | -4314.1% |
| FY2023 | 2023-12-31 | (206K) | +82.8% |
| FY2022 | 2022-12-31 | (1.2M) | -10.7% |
| FY2021 | 2021-12-31 | (1.09M) | — |
Capital Expenditures vs competitors
How RNAC compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -53.9% is the lowest of 7, against a peer median of +0.4%.
- Capital expenditures amounts to 248.2% of revenue for RNAC, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.46M USD | +8.2% | +114.9% | 44.6% | |
| LTM Mar 2026 | $4.41M USD | -53.9% | +65.6% | 248.2% | |
| LTM Mar 2026 | $1.57M USD | -7.4% | -18.1% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $728.23K USD | +188.5% | +36.5% | — |
| LTM Mar 2026 | $561K USD | +42.7% | -6.1% | 1.7% | |
| FY2025 | €237.26K EUR | -28.8% | -24.9% | 5.3% | |
| LTM Mar 2026 | $95K USD | -8.7% | — | — | |
| LTM Mar 2026 | $8 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding RNAC) | — | +0.4% | -6.1% | 1.7% | |
Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.69M) | 35.38M | (219.71M) | (77.42M) | (130.3M) |
| Depreciation & Amortization | 1.25M | 1.29M | 843K | 1.15M | 2.96M |
| Deferred Income Tax | 2.4M | (21.4M) | (19M) | 287K | (9.19M) |
| Stock-Based Compensation | 7.72M | 11.19M | 22.52M | 6.58M | 10.52M |
| Change in Working Capital | (48.19M) | (60.38M) | 4.97M | (5.79M) | (8.06M) |
| Accounts Receivables | (2.69M) | 3.32M | 907K | 7.98M | (243K) |
| Inventory | 211K | 920K | 0 | 0 | 0 |
| Accounts Payables | (219K) | 92K | 2.83M | (2.93M) | 1.07M |
| Other Working Capital | (45.5M) | (64.71M) | 1.23M | (10.84M) | (8.89M) |
| Other Non-Cash Items | 2.13M | 2.29M | 159.21M | 51.52M | 60.14M |
| Operating Cash Flow | (60.38M) | (31.63M) | (51.16M) | (23.67M) | (73.94M) |
| Capital Expenditures | (1.09M) | (1.2M) | (206K) | (9.09M) | (5.45M) |
| Acquisitions (Net) | 0 | 0 | 6.56M | 351K | 0 |
| Purchases of Investments | (32.46M) | (33.5M) | 0 | 0 | 0 |
| Sales of Investments | 16.4M | 19.7M | 28.25M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (17.14M) | (15M) | 34.61M | (8.74M) | (5.45M) |
| Debt Repayment | 0 | 0 | (27.46M) | 0 | 0 |
| Common Stock Issued | 51.96M | 38.98M | 0 | 124.44M | (301K) |
| Common Stock Repurchased | 0 | 0 | (6.17M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 235K | 231K | 3.99M | (7.75M) |
| Financing Cash Flow | 52.9M | 39.22M | (13.15M) | 168.43M | (8.06M) |
| Effect of Forex Changes | (3K) | 20K | (53K) | (21K) | 45K |
| Net Change in Cash | (24.63M) | (7.4M) | (29.75M) | 135.99M | (87.41M) |
| Free Cash Flow | (61.47M) | (32.83M) | (51.37M) | (32.77M) | (79.4M) |
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Intrinsic Alpha fair value
Locked
Current Price
$6.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.